Edwards Lifesciences Corp·4

Feb 5, 6:37 PM ET

MUSSALLEM MICHAEL A 4

4 · Edwards Lifesciences Corp · Filed Feb 5, 2024

Insider Transaction Report

Form 4
Period: 2024-02-05
MUSSALLEM MICHAEL A
DirectorChairman & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2024-02-05$36.75/sh+29,350$1,078,61333,835.82 total
  • Sale

    Common Stock

    2024-02-05$88.63/sh6,422$569,18226,413.82 total
  • Exercise/Conversion

    Employee Stock Option (Right to Acquire)

    2024-02-0529,35088,050 total
    Exercise: $36.75From: 2017-06-11Exp: 2024-05-10Common Stock (29,350 underlying)
  • Sale

    Common Stock

    2024-02-05$86.44/sh9,761$843,74116,652.82 total
  • Sale

    Common Stock

    2024-02-05$89.61/sh1,000$89,61032,835.82 total
  • Sale

    Common Stock

    2024-02-05$87.55/sh12,167$1,065,2214,485.82 total
Holdings
  • Common Stock

    (indirect: By Trust)
    4,038,377
Footnotes (5)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
  • [F2]This transaction was executed in multiple trades at prices ranging from $89.390 to $90.080. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $88.210 to $89.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This transaction was executed in multiple trades at prices ranging from $86.100 to $87.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]This transaction was executed in multiple trades at prices ranging from $87.110 to $88.105. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file
  • 4
    doc4.xmlPrimary